10 U/ml (OR 2.86, p 0.01) remained the only independent factors to predict ovarian cancer recurrence. Conclusions The present paper proposes the validation of a novel CA125 algorithm aiming to detect recurrent EOC. These data may allow us to investigate novel ways of follow up that do not require a patient's physical attendance at a clinic (virtual follow-up)."/>
Skip to main content

Table 1 Baseline characteristics of Patients included in this study

From: The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study

Characteristic Values
Age, mean (SD) [years] 62.2 (10.8)
Pre-op CA125, median (IQR) 305 (136-894)
FIGO stages (3 or 4), n (%) 45 (80.4)
No residual disease, n (%) 29 (51.8)
Surgical procedures, n (%)  
   Salpingo oophorectomy 54 (96.4)
   Omentectomy 49 (87.5)
   Pelvic Lymph node dissection 45 (80.4)
   Hysterectomy 41 (73.2)
   Aortic Lymph node dissection 39 (69.6)
   Appendicectomy 26 (46.4)
   Rectal resection 13 (23.2)
   Liver/Spleen resection 5 (8.9)
   Vaginectomy 5 (8.9)
   Small bowel resection 4 (7.1)
   Diaphragm 3 (5.4)
   Ureter 3 (5.4)
   Others* 8 (14.3)
Cell type  
   Serous, n (%) 36 (64.3)
   Other, n (%) 20 (35.7)
Grade, n (%)  
   1 4 (7.1)
   2 14 (25.0)
   3 38 (67.9)
Relapse, n (%) 29 (51.8)
Relapse, detected by, n (%)  
   CA125 alone 14 (48.3)
   CA125 plus any other (imaging, clinical) 8 (27.6)
   CA125 not elevated 7 (24.1)
  1. *Abdominal wall resection; thoracoscopic surgery; hernia repair; distal pancreatectomy; hemicolectomy; large bowel resection.